ARCHIVES

EPO Controversy: ODAC To Review EPO Agents in May; SEC Probes Amgen’s Delay in Study Disclosure.

This article is from The Cancer Letter archive.

Vol. 33 No. 08 | March 2, 2007

Download PDF Visit The Full Archive

Related Articles

NCI Intramural Budget: Well-Funded Labs, High Costs, Or Deceiving Appearances?

April 21, 1995

NCI Advisory Group, Other Cancer Meetings For May, June

April 30, 1976

In Brief: Surgeons Oncology Group Gets NCI Funding To Conduct Multicenter Clinical Trials

April 17, 1998

Dole Visits Roswell Park, Hails PSA Test

January 28, 1994

NCI Calls Fisher “A Dominant Force” In Breast Cancer

September 5, 1997

Also Kevin Cullen named director, Univ. of Maryland Greenebaum Cancer Center.

November 28, 2003